Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
10:51am, Wednesday, 05'th Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
White House speaking with Novo Nordisk, Eli Lilly about selling some obesity drugs for $149/mo: WSJ
07:13am, Wednesday, 05'th Nov 2025
CNBC's Andrew Ross Sorkin reports on the latest news.
This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?
06:30am, Wednesday, 05'th Nov 2025
Tirzepatide is used to treat both diabetes and obesity. Eli Lilly just struck a major deal with the world's largest retailer.
XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
05:00am, Wednesday, 05'th Nov 2025
SHANGHAI , Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategi
Stanley Druckenmiller has a fantastic investing track record, delivering a double-digit average annual return over time. The billionaire sold artificial intelligence (AI) leaders Nvidia and Palantir -
Obesity drugs may get Medicare access under deal with White House: reports
05:29pm, Tuesday, 04'th Nov 2025
The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain Medica
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 04'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints New reports
10:44am, Tuesday, 04'th Nov 2025
Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in return for coverage of products under Medicare,
International Markets and Lilly (LLY): A Deep Dive for Investors
10:16am, Tuesday, 04'th Nov 2025
Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 04'th Nov 2025
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Best Medical Stocks To Watch Today – November 2nd
03:05am, Tuesday, 04'th Nov 2025
Eli Lilly and Company, Pfizer, UnitedHealth Group, AbbVie, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. "Medical stocks" are share
Top Pharmaceutical Stocks To Follow Now – November 2nd
03:05am, Tuesday, 04'th Nov 2025
Eli Lilly and Company, Pfizer, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded compani
Lilly to build $3 billion Dutch plant to boost weight-loss pill production
08:32am, Monday, 03'rd Nov 2025
Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other or
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
08:30am, Monday, 03'rd Nov 2025
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain INDIANAPOLIS , Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NY
Where the blockbuster weight loss drug market stands today — and what's coming next
08:00am, Sunday, 02'nd Nov 2025
The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their med
